Epizyme, Inc.,
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$30.8M
Doctors Paid
2,973
Transactions
11,678
2024 Total
$8.1M
Payment Breakdown by Category
Research$29.4M (95.4%)
Food & Beverage$143,748 (0.5%)
Consulting$101,122 (0.3%)
Travel$42,068 (0.1%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $29.4M | 5,152 | 95.4% |
| Honoraria | $1.0M | 708 | 3.4% |
| Food and Beverage | $143,748 | 5,122 | 0.5% |
| Consulting Fee | $101,122 | 24 | 0.3% |
| Grant | $50,000 | 1 | 0.2% |
| Travel and Lodging | $42,068 | 125 | 0.1% |
| Education | $26,675 | 539 | 0.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,337 | 5 | 0.0% |
| Space rental or facility fees (teaching hospital only) | $9,500 | 2 | 0.0% |
Payments by Type
Research
$29.4M
5,152 transactions
General
$1.4M
6,526 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| Symphony-1: A Phase 1b/3 Double-Blind, Randomized, Active-Controlled, 3-Stage, Biomarker Adaptive Study Of Tazemetostat Or Placebo In Combination With Lenalidomide Plus Rituximab In Subjects With Relapsed/Refractory Follicular Lymphoma | $8.8M | 1 | 2,924 |
| A PHASE 1B/3 DOUBLE-BLIND, RANDOMIZED, ACTIVE-CONTROLLED, 3-STAGE, BIOMARKER ADAPTIVE STUDY OF TAZEMETOSTAT OR PLACEBO IN COMBINATION WITH LENALIDOMIDE PLUS RITUXIMAB IN SUBJECTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA | $5.2M | 0 | 519 |
| A Phase Ia/Ib study of talazoparib in combination with tazemetostat in metastatic castration-resistant prostate cancer (mCRPC) | $1.5M | 0 | 3 |
| A Phase Ia/Ib Study of Talazoparib in Combination With Tazemetostat in Metastatic Castration-resistant Prostate Cancer (mCRPC) | $1.1M | 0 | 4 |
| A PHASE 1B/2 OPEN-LABEL STUDY EVALUATING TAZEMETOSTAT IN COMBINATION WITH ENZALUTAMIDE OR ABIRATERONE/PREDNISONE IN CHEMOTHERAPY NAIVE SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | $1.0M | 1 | 109 |
| A Single Arm Phase I/II Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma Big Ten Cancer Research Consortium BTCRC-LYM20-463 | $1.0M | 0 | 10 |
| A Phase 1/1b, Open-Label, Multi-Center, Two-Part Study of SETD2 Inhibitor EZM0414 in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma | $986,018 | 0 | 167 |
| CELLO-1: A Phase 1b/2 Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer | $929,500 | 0 | 319 |
| A PHASE1B/3 GLOBAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF TAZEMETOSTAT IN COMBINATION WITH DOXORUBICIN AS FRONTLINE THERAPY FOR ADVANCED EPITHELIOID SARCOMA | $807,277 | 0 | 102 |
| A PHASE 1B/2 OPEN-LABEL STUDY IN CHEMOTHERAPY NAIVE SUBJECTS WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER | $739,947 | 0 | 96 |
| A Single Arm Phase I/II Study of Tazemetostat with Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma | $739,685 | 0 | 10 |
| A Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation | $633,500 | 0 | 3 |
| A PHASE 1, OPEN-LABEL MULTI-DOSE TWO-PART STUDY TO CHARACTERIZE THE EFFECTS OF A STRONG CYP3A4 INHIBITOR ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT (EPZ-6438), AND THE EFFECTS OF A STRONG CYP3A4 INDUCER ON THE STEADY-STATE PHARMACOKINETICS OF TAZEMETOSTAT IN SUBJECTS WITH ADVANCED MALIGNANCIES | $611,401 | 0 | 61 |
| A PHASE 2, MULTICENTER STUDY OF THE EZH2 INHIBITOR TAZEMETOSTAT IN ADULT SUBJECTS WITH INI1-NEGATIVE TUMORS OR RELAPSED/REFRACTORY SYNOVIAL SARCOMA | $475,740 | 0 | 69 |
| A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma | $468,754 | 0 | 68 |
| A PHASE I, OPEN-LABEL SINGLE-DOSE PHARMACOKINETIC AND SAFETY STUDY OF ORAL TAZEMETOSTAT IN SUBJECTS WITH MODERATE AND SEVERE HEPATIC IMPAIRMENT WITH ADVANCED MALIGNANCIES | $435,003 | 0 | 68 |
| A feasibility trial of tazemetostat plus CAR T cell therapy in B-cell lymphomas | $395,850 | 0 | 3 |
| A Phase II trial of tazemetostat plus mosunetuzumab in untreated follicular lymphoma | $377,000 | 0 | 2 |
| A PHASE 1 STUDY OF THE EZH2 INHIBITOR TAZEMETOSTAT IN PEDIATRIC SUBJECTS WITH RELAPSED OR REFRACTORY INI1-NEGATIVE TUMORS OR SYNOVIAL SARCOMA | $300,032 | 0 | 49 |
| E7438-G000-101 | $281,992 | 0 | 86 |
| A Phase II Open-Label, Multicenter trial of oral Tazemetostat in combination with Rituximab in Subjects with Relapsed/Refractory Follicular Lymphoma | $249,916 | 0 | 1 |
| Phase I trial of tazemetostat in combination with venetoclax in patients with non-Hodgkin lymphoma | $226,200 | 0 | 2 |
| Tazemetostat Rollover Study (TRuST): An Open-Label, Rollover Study | $210,749 | 0 | 91 |
| A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies | $202,109 | 0 | 65 |
| A Phase 1b/3 Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma | $186,310 | 0 | 88 |
| A Single Arm Phase I/II Study of Tazemetostat With Rituximab and Abbreviated Bendamustine in the Frontline Treatment of High Tumor Burden Follicular Lymphoma Big Ten Cancer Research | $166,251 | 0 | 1 |
| A Prospective Observational International Study of Cabozantinib Tablets in Combination With Nivolumab as First-line Treatment of Advanced Renal Cell Carcinoma in Adults | $155,135 | 0 | 19 |
| Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Phase 1-2 Trial | $154,222 | 0 | 2 |
| Phase I Trial of Tazemetostat in Combination With Venetoclax in Patients With Relapsed/Refractory Non-Hodgkin Lymphoma | $150,800 | 0 | 2 |
| A Phase I, Open-label Multi-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies | $116,818 | 0 | 46 |
Payments by Medical Specialty
Top Paid Doctors — Page 2
| Doctor | Specialty | Location | Total | 2022 |
|---|---|---|---|---|
| Francisco Hernandez-Ilizaliturri, Md, MD | Internal Medicine | Buffalo, NY | $9,804 | $0 |
| Dr. Matthew Lunning, D.o, D.O | Internal Medicine | Omaha, NE | $9,712 | $0 |
| Dr. Peter Martin, M.d, M.D | Hematology & Oncology | New York, NY | $9,441 | $0 |
| Laura Mulka, Aprn, APRN | Nurse Practitioner | Wethersfield, CT | $8,825 | $0 |
| Dr. Julio Chavez, Md, MD | Medical Oncology | Tampa, FL | $8,671 | $0 |
| Jeremy Abramson, Md, MD | Medical Oncology | Boston, MA | $8,250 | $0 |
| Kasra Karamlou, M.d, M.D | Hematology & Oncology | Sandusky, OH | $8,103 | $0 |
| Rafat Ansari, M.d, M.D | Hematology & Oncology | Mishawaka, IN | $7,675 | $0 |
| Ambreen Ijaz, M.d, M.D | Medical Oncology | Augusta, ME | $7,600 | $0 |
| Dr. Morton Coleman, Md, MD | Hematology & Oncology | New York, NY | $7,428 | $0 |
| Dr. Ashwani Agarwal, M.d, M.D | Medical Oncology | Dallas, TX | $7,414 | $0 |
| Dr. Jorge Leguizamo, M.d, M.D | Hematology & Oncology | Lawrenceville, GA | $7,401 | $0 |
| Dr. Steven Hager, D.o, D.O | Hematology & Oncology | Fresno, CA | $7,345 | $0 |
| Amitkumar Mehta | Hematology & Oncology | Birmingham, AL | $7,189 | $0 |
| Dr. Priya Rudolph, Md, Phd, MD, PHD | Hematology & Oncology | Athens, GA | $7,010 | $0 |
| Franklin Chu, Md, MD | Urology | San Bernardino, CA | $7,000 | $0 |
| Michael Schuster, Md, MD | Internal Medicine | New York, NY | $6,919 | $0 |
| Dr. Habte Yimer, M.d, M.D | Hematology | Tyler, TX | $6,658 | $0 |
| Alex Mejia Garcia, M.d, M.D | Hematology & Oncology | Vero Beach, FL | $6,643 | $0 |
| Dr. Javier Munoz, M.d., M.s., F.a.c.p, M.D., M.S., F.A.C.P | Internal Medicine | Phoenix, AZ | $6,642 | $0 |
| Dr. Faithlore Gardner, Md, MD | Medical Oncology | Cape Coral, FL | $6,546 | $0 |
| Loretta Nastoupil, M.d, M.D | Hematology | Houston, TX | $6,525 | $0 |
| Lauren Pinter-Brown, Md, MD | Hematology & Oncology | Los Angeles, CA | $6,424 | $0 |
| Susan Utley, Np, NP | Nurse Practitioner | Nashville, TN | $6,412 | $0 |
| Dr. Sujith Kalmadi, Md, MD | Hematology & Oncology | Chandler, AZ | $6,259 | $0 |
About Epizyme, Inc.,
Epizyme, Inc., has made $30.8M in payments to 2,973 healthcare providers, recorded across 11,678 transactions in the CMS Open Payments database. In 2024, the company paid $8.1M. The top product by payment volume is Tazverik ($18.8M).
Payments were distributed across 74 medical specialties. The top specialty by payment amount is Hematology & Oncology ($588,367 to 1,031 doctors).
Payment categories include: Food & Beverage ($143,748), Consulting ($101,122), Research ($29.4M), Travel & Lodging ($42,068).
Epizyme, Inc., is associated with 2 products in the CMS Open Payments database.